Modelling landscape management scenarios for equitable and sustainable futures in rural areas based on ecosystem services

Scenario analysis is a useful technique to inform landscape planning of social-ecological systems by modelling future trends in ecosystem service supply and distribution. This is especially critical in floodplain agroecosystems of rural areas, which are at risk of losing riparian forest corridors due to increasing land use conversion for agricultural production and other ecosystem services due to rural abandonment. However, few studies investigating the effects of land management combine social and ecological modelling in scenario analyses. We estimated the supply of 16 ecosystem services under five alternative scenarios along two gradients: agricultural intensification of the floodplain and active ecological restoration of the riparian forest. We used redundancy analyses to detect ecosystem service bundles and interviews to identify societal gains and losses associated with each management scenario. Our results show how land management influences both the supply and distribution of ecosystem services. Scenarios promoting active ecological restoration supplied more services and benefited a larger range of societal sectors than scenarios focused on provisioning services. We also found two consistent bundles across scenarios, one related to less intensive food supply and another one related to outdoor activities. Interestingly, additional services were included in these bundles in the different scenarios, reflecting land management effects. Landscape scale management promoting both the conservation of ecosystem functioning and the sustainable use of provisioning services could supply a more balanced set of ecosystem services and benefit a larger number of societal sectors, contributing to more equitable and sustainable futures in rural areas

CHEMICAL ATTRIBUTES OF PROPERTIES IN SOIL SUBMITTED TO SUCCESSIVE APPLICATIONS OF PIG SLURRY IN BRAÇO DO NORTE CITY, SANTA CATARINA STATE

In Santa Catarina (SC) State, pigs are produced in intensive system and the pig slurry generated is used as organic fertilizer in crops and pasture. This study aimed to evaluate changes of chemical attributes in soil with successive applications of pig slurry in properties located at Braço do Norte (SC) city. In September 2009 questionnaires were applied to characterize the production system of pigs and management of pig slurry in six properties in two micro regions, located at Braço do Norte (SC) city. Soil samples were collected (layer 0-20 cm) and the organic matter, pH, P, K, Al, Ca, Mg, Zn, Cu and Mn were analyzed. Successive applications of pig slurry, in the properties, in two micro regions of Braço do Norte City, Santa Catarina State, Southern Brazil, increased the content of phosphorus and potassium until very high and copper and zinc until high.No estado de Santa Catarina (SC) os suínos são produzidos em sistema de criação intensiva e os dejetos gerados são usados como adubo orgânico em sistemas de cultivos anuais ou pastagens. O presente trabalho teve como objetivo avaliar as alterações de atributos químicos do solo, submetidos a aplicações sucessivas de dejetos de suínos em seis propriedades suinícolas no Município de Braço do Norte (SC), cultivadas com culturas anuais e pastagens. Em setembro de 2009 foram aplicados questionários para a caracterização do sistema produtivo de suínos e do manejo dos dejetos em seis propriedades nas Microbacias Rio Coruja/Bonito e Rio Cachorrinhos, no município de Braço do Norte (SC). Na mesma data foram coletadas amostras de solo, na camada de 0-20 cm, em áreas com culturas anuais e pastagem das propriedades e áreas de mata nativa. O solo foi seco, moído, passado em peneira e preparado para a análise de matéria orgânica, pH em água, P disponível, K trocável e, Al, Ca, Mg trocáveis e, Zn, Cu e Mn. As aplicações sucessivas de dejetos de suínos líquidos ao longo dos anos na maioria das propriedades, localizadas em duas Microbacias da Região Sul de Santa Catarina, elevaram os teores de fósforo disponível e de potássio trocável até muito alto e os de cobre, zinco e manganês até alto

Iron deficiency in chronic heart failure: case-based practical guidance

In patients with chronic heart failure, iron deficiency, even in the absence of anaemia, can aggravate the underlying disease and have a negative impact on clinical outcomes and quality of life. The 2016 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure recognize iron deficiency as a co-morbidity in chronic heart failure and recommend iron status screening in all newly diagnosed patients with chronic heart failure. Furthermore, the guidelines specifically recommend considerations of intravenous iron therapy, ferric carboxymaltose, for the treatment of iron deficiency. However, in spite of these recommendations, iron deficiency remains often overlooked and undertreated. This may be due, in part, to the lack of clinical context and practical guidance accompanying the guidelines for the treating physician. Here, we provide practical guidance complemented by a case study to assist and improve the timely diagnosis, treatment, and routine management of iron deficiency in patients with chronic heart failure

INTERFERÊNCIA DE PLANTAS DE COBERTURA SOBRE A INCIDÊNCIA DE PLANTAS INVASORAS E A PRODUÇÃO DE CEBOLA SOB SISTEMA DE PLANTIO DIRETO

Mesmo com expectativas de expansão das áreas agrícolas brasileiras sob sistema de plantio direto (SPD), são poucos os trabalhos sobre o controle de plantas invasoras sem o uso de herbicidas, principalmente na produção de hortaliças, como a cebola. Para tanto, culturas utilizadas para cobertura do solo se mostram eficientes no controle do desenvolvimento de plantas invasoras através da inibição física e/ou alelopática. O objetivo do presente trabalho foi avaliar diferentes espécies de cobertura do solo, em sistemas em monocultivo ou consorciados, no controle de plantas invasoras e a sua interferência na produção de cebola sob SPD em transição agroecológica. O experimento foi instalado na Estação Experimental da Epagri em Ituporanga (SC), em um Cambissolo Húmico. Os tratamentos foram: T1: testemunha (vegetação invasora); T2: aveia preta (Avena strigosa); T3: centeio (Secale cereale); T4: nabo-forrageiro (Raphanus sativus); T5: consócio de nabo-forrageiro e centeio; T6: consórcio de nabo-forrageiro e aveia preta. Os tratamentos nabo-forrageiro e nabo-forrageiro + centeio aos 60 dias após a semeadura (DAS) e centeio e nabo-forrageiro + centeio aos 120 DAS propiciaram a maior produção de matéria seca de plantas de cobertura, enquanto a menor produção de matéria seca de plantas invasoras foi obtida nos tratamentos nabo-forrageiro + centeio, seguido de nabo-forrageiro no início do ciclo da cebola. A maior produção de bulbos de cebola da classe 3 (50mm≤ᶲ˂70mm) e total, em relação à testemunha, também foi obtida nestes dois tratamentos

Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management

Iron deficiency, even in the absence of anemia, can be debilitating, and exacerbate any underlying chronic disease, leading to increased morbidity and mortality. Iron deficiency is frequently concomitant with chronic inflammatory disease; however, iron deficiency treatment is often overlooked, partially due to the heterogeneity among clinical practice guidelines. In the absence of consistent guidance across chronic heart failure, chronic kidney disease and inflammatory bowel disease, we provide practical recommendations for iron deficiency to treating physicians: definition, diagnosis, and disease‐specific diagnostic algorithms. These recommendations should facilitate appropriate diagnosis and treatment of iron deficiency to improve quality of life and clinical outcomes

Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial

Aim: Patients with diabetes mellitus are at high risk of adverse events after percutaneous revascularization, with no differences in outcomes between most contemporary drug-eluting stents. The Cre8 EVO stent releases a formulation of sirolimus with an amphiphilic carrier from laser-dug wells, and has shown clinical benefits in diabetes. We aimed to compare Cre8 EVO stents to Resolute Onyx stents (a contemporary polymer-based zotarolimus-eluting stent) in patients with diabetes. Methods and results: We did an investigator-initiated, randomized, controlled, assessor-blinded trial at 23 sites in Spain. Eligible patients had diabetes and required percutaneous coronary intervention. A total of 1175 patients were randomly assigned (1:1) to receive Cre8 EVO or Resolute Onyx stents. The primary endpoint was target-lesion failure, defined as a composite of cardiac death, target-vessel myocardial infarction, and clinically indicated target-lesion revascularization at 1-year follow-up. The trial had a non-inferiority design with a 4% margin for the primary endpoint. A superiority analysis was planned if non-inferiority was confirmed. There were 106 primary events, 42 (7.2%) in the Cre8 EVO group and 64 (10.9%) in the Resolute Onyx group [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.44 to 0.96; pnon-inferiority <0.001; psuperiority = 0.030]. Among the secondary endpoints, Cre8 EVO stents had significantly lower rate than Resolute Onyx stents of target-vessel failure (7.5% vs 11.1%, HR 0.67, 95% CI 0.46 to 0.99; p = 0.042). Probable or definite stent thrombosis and all-cause death were not significantly different between groups. Conclusions: In patients with diabetes, Cre8 EVO stents were non-inferior to Resolute Onyx stents with regard to target-lesion failure composite outcome. An exploratory analysis for superiority at 1 year suggests that the Cre8 EVO stents might be superior to Resolute Onyx stents with regard to the same outcome

The GRAVITY+ Project: Towards All-sky, Faint-Science, High-Contrast Near-Infrared Interferometry at the VLTI

The GRAVITY instrument has been revolutionary for near-infrared interferometry by pushing sensitivity and precision to previously unknown limits. With the upgrade of GRAVITY and the Very Large Telescope Interferometer (VLTI) in GRAVITY+, these limits will be pushed even further, with vastly improved sky coverage, as well as faint-science and high-contrast capabilities. This upgrade includes the implementation of wide-field off-axis fringe-tracking, new adaptive optics systems on all Unit Telescopes, and laser guide stars in an upgraded facility. GRAVITY+ will open up the sky to the measurement of black hole masses across cosmic time in hundreds of active galactic nuclei, use the faint stars in the Galactic centre to probe General Relativity, and enable the characterisation of dozens of young exoplanets to study their formation, bearing the promise of another scientific revolution to come at the VLTI.Comment: Published in the ESO Messenge

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial

Aims The objective of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) was to determine whether aliskiren, a direct renin inhibitor, would improve post-discharge outcomes in patients with hospitalization for heart failure (HHF) with reduced ejection fraction. Pre-specified subgroup analyses suggested potential heterogeneity in post-discharge outcomes with aliskiren in patients with and without baseline diabetes mellitus (DM). Methods and results ASTRONAUT included 953 patients without DM (aliskiren 489; placebo 464) and 662 patients with DM (aliskiren 319; placebo 343) (as reported by study investigators). Study endpoints included the first occurrence of cardiovascular death or HHF within 6 and 12 months, all-cause death within 6 and 12 months, and change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at 1, 6, and 12 months. Data regarding risk of hyperkalaemia, renal impairment, and hypotension, and changes in additional serum biomarkers were collected. The effect of aliskiren on cardiovascular death or HHF within 6 months (primary endpoint) did not significantly differ by baseline DM status (P = 0.08 for interaction), but reached statistical significance at 12 months (non-DM: HR: 0.80, 95% CI: 0.64-0.99; DM: HR: 1.16, 95% CI: 0.91-1.47; P = 0.03 for interaction). Risk of 12-month all-cause death with aliskiren significantly differed by the presence of baseline DM (non-DM: HR: 0.69, 95% CI: 0.50-0.94; DM: HR: 1.64, 95% CI: 1.15-2.33; P < 0.01 for interaction). Among non-diabetics, aliskiren significantly reduced NT-proBNP through 6 months and plasma troponin I and aldosterone through 12 months, as compared to placebo. Among diabetic patients, aliskiren reduced plasma troponin I and aldosterone relative to placebo through 1 month only. There was a trend towards differing risk of post-baseline potassium ≥6 mmol/L with aliskiren by underlying DM status (non-DM: HR: 1.17, 95% CI: 0.71-1.93; DM: HR: 2.39, 95% CI: 1.30-4.42; P = 0.07 for interaction). Conclusion This pre-specified subgroup analysis from the ASTRONAUT trial generates the hypothesis that the addition of aliskiren to standard HHF therapy in non-diabetic patients is generally well-tolerated and improves post-discharge outcomes and biomarker profiles. In contrast, diabetic patients receiving aliskiren appear to have worse post-discharge outcomes. Future prospective investigations are needed to confirm potential benefits of renin inhibition in a large cohort of HHF patients without D

Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial.

AIM: Patients with diabetes mellitus are at high risk of adverse events after percutaneous revascularization, with no differences in outcomes between most contemporary drug-eluting stents. The Cre8 EVO stent releases a formulation of sirolimus with an amphiphilic carrier from laser-dug wells, and has shown clinical benefits in diabetes. We aimed to compare Cre8 EVO stents to Resolute Onyx stents (a contemporary polymer-based zotarolimus-eluting stent) in patients with diabetes. METHODS AND RESULTS: We did an investigator-initiated, randomized, controlled, assessor-blinded trial at 23 sites in Spain. Eligible patients had diabetes and required percutaneous coronary intervention. A total of 1175 patients were randomly assigned (1:1) to receive Cre8 EVO or Resolute Onyx stents. The primary endpoint was target-lesion failure, defined as a composite of cardiac death, target-vessel myocardial infarction, and clinically indicated target-lesion revascularization at 1-year follow-up. The trial had a non-inferiority design with a 4% margin for the primary endpoint. A superiority analysis was planned if non-inferiority was confirmed. There were 106 primary events, 42 (7.2%) in the Cre8 EVO group and 64 (10.9%) in the Resolute Onyx group [hazard ratio (HR): 0.65, 95% confidence interval (CI): 0.44-0.96; Pnon-inferiority < 0.001; Psuperiority = 0.030]. Among the secondary endpoints, Cre8 EVO stents had significantly lower rate than Resolute Onyx stents of target-vessel failure (7.5% vs. 11.1%, HR: 0.67, 95% CI: 0.46-0.99; P = 0.042). Probable or definite stent thrombosis and all-cause death were not significantly different between groups. CONCLUSION: In patients with diabetes, Cre8 EVO stents were non-inferior to Resolute Onyx stents with regard to target-lesion failure composite outcome. An exploratory analysis for superiority at 1 year suggests that the Cre8 EVO stents might be superior to Resolute Onyx stents with regard to the same outcome. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT03321032